PRVB / Provention Bio: Tzield Finally Approved, But Neutral On Its Commercial Launch

Sanofi plans to acquire Provention Bio for around $2.9 billion. The deal will add Provention's type 1 diabetes drug Tzield to Sanofi's lineup. more_horizontal

Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023. more_horizontal

Provention Bio (NASDAQ: PRVB ) stock is rocketing higher on Monday following news that Sanofi (NASDAQ: SNY ) is acquiring the company. That deal ha more_horizontal

RED BANK, N.J. , Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercept more_horizontal

PRVB got its teplizumab approved last year. The molecule is a wonderful new addition to T1D therapy; however, it has been in development for decades. more_horizontal

Provention Bio, Inc. (PRVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might more_horizontal

Provention Bio, Inc. (PRVB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound more_horizontal

Received FDA approval of TZIELD for Stage 2 Type 1 Diabetes patients in November of 2022. Potential to increase market potential of TZIELD with ongoin more_horizontal